Evidence map›Paper›PMID 26886710›Full record

ReviewDer Internist2016

[Current therapeutic strategies for mantle cell lymphoma].

M Dreyling, A Schnaiter, C Schmidt, E Hoster

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Internist, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

M DreylingMedizinische Klinik und Poliklinik III, Klinikum der Universität München, Marchioninistr. 15, 81337, München, Deutschland. martin.dreyling@med.uni-muenchen.de.
A SchnaiterMedizinische Klinik und Poliklinik III, Klinikum der Universität München, Marchioninistr. 15, 81337, München, Deutschland.
C SchmidtMedizinische Klinik und Poliklinik III, Klinikum der Universität München, Marchioninistr. 15, 81337, München, Deutschland.
E HosterMedizinische Klinik und Poliklinik III, Klinikum der Universität München, Marchioninistr. 15, 81337, München, Deutschland.
LMU Klinikum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mantle cell lymphoma is a subtype of B‑cell lymphoma with a mostly aggressive behavior and poor long-term prognosis. The choice of therapy depends on the age, performance status and risk profile of the patient. Randomized trials have confirmed the superiority of a dose-intensified induction therapy containing cytarabine followed by autologous stem cell transplantation in the first-line treatment of younger patients with a good general condition. Elderly patients benefit from a rituximab maintenance therapy after immunochemotherapy. Novel targeted therapies of the B‑cell receptor pathway with the Bruton's tyrosine kinase inhibitor ibrutinib and the mechanistic target of rapamycin (mTOR) antagonist temsirolimus as well as immunomodulatory drugs (lenalidomide) have shown promising results in relapsed disease. The proteasome inhibitor bortezomib has been approved for first-line treatment in combination with conventional chemotherapy.

Indexed as

Antineoplastic AgentsChemoradiotherapyCombined Modality TherapyEvidence-Based MedicineHumansImmunotherapyLymphoma, Mantle-CellMolecular Targeted TherapyRadiotherapyRituximabTreatment OutcomeAntineoplastic AgentsRituximabAutologous transplantationB-cell lymphomaImmunochemotherapyReceptor pathwaysTargeted therapy

Identifiers

PMID26886710
OpenAlexW2281009501

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.